Clidinium

Evidence Level: L5

Predicted Indications: 9

Clidinium

Pharmacist Assessment Report

Clidinium: quaternary antimuscarinic → cauda equina syndrome (cauda equina syndrome)

One-Sentence Summary

Clidinium is a quaternary antimuscarinic (anticholinergic) drug, marketed in Canada under the brand LIBRAX. The TxGNN model predicts it may be useful for cauda equina syndrome (score 0.9993), but there are 0 clinical trials and 0 publications that study this disease directly. This is a model prediction only, and the anticholinergic action could worsen urinary retention, a common feature of the condition.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	cauda equina syndrome (cauda equina syndrome)
TxGNN Prediction Score	0.9993
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Clidinium is known as a quaternary antimuscarinic, which blocks muscarinic receptors and reduces smooth-muscle contraction and secretions.

A theoretical link to cauda equina syndrome would run through reduced detrusor overactivity in bladder dysfunction that follows nerve-root involvement. This link is speculative. The condition commonly involves urinary retention, and an anticholinergic could make that worse, so the prediction may be unsafe rather than helpful.

The score is high, but a score alone is not clinical evidence. No trial or publication supports this use.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00115630	LIBRAX	Not recorded	Not recorded

Safety Considerations

Conditions flagged as possible contraindications in the data compiled for this report (these are database relations, not label text): hypertension, gastric ulcer, anxiety and neurotic disorders, porphyria, kidney disease, liver disease, gallbladder disease, psychotic disorders, benign prostatic hyperplasia, coronary artery disease, sleep apnea syndromes, angle-closure glaucoma, myasthenia gravis and other neuromuscular junction diseases, and lung disease.
Drug Interactions: 100 interactions were found. Examples at moderate level include:
- Opioids: fentanyl, alfentanil, codeine, dihydrocodeine, hydrocodone, tramadol
- Other anticholinergic or antimuscarinic agents: aclidinium, hyoscyamine, amitriptyline, amantadine
- Other agents: ethanol, loperamide, botulinum toxin type A, phenylephrine, acebutolol, acetylcholine, acrivastine, phenyltoloxamine
Minor-level examples: acetaminophen, hydrochlorothiazide.

Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score only. No trial or publication addresses cauda equina syndrome, so the evidence level is L5. The anticholinergic effect may worsen urinary retention, which raises a safety concern.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications
Mechanism-of-action data
A safety assessment of anticholinergic effects on bladder emptying in nerve-root compression
Any clinical or case-level evidence in this condition before further evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.